Canada: Convergence And Divergence On Securities Class Actions

The United States Supreme Court takes a new approach on the standards for certification.

The class action is a litigation technique that lends itself well to claims by security-holders against issuers. The classes of purchasers of securities are easily definable, the losses are often all too publicly ascertainable, and the procedural benefits of one large claim (as opposed to a multitude of related actions in various jurisdictions) are clear. Securities class actions can grow, geographically, depending on where the securities were issued. With increased integration of the Canadian and global (particularly American) capital markets, more and larger class action claims by disgruntled shareholders and bondholders can be expected.

Against this backdrop, a key pronouncement has been made by The United States Supreme Court in the much-publicized Amgen Inc. et al. v. Connecticut Retirement Plans and Trust Funds1 ("Amgen") decision, handed down on February 27, 2013. The court found that proof of materiality is not a prerequisite to certification of a securities class action. This is a significant development, opening the door in the United States to yet greater potential liability for capital markets participants. The decision in the Amgen case gives us cause to examine the regime for certifying securities class actions in both countries. The significance of certification cannot be underestimated.

Materiality Matters

Most securities lawsuits are based in fraudulent or negligent misrepresentation – the typical scenario is that either the offering documents or the continuous disclosure is alleged to be, by misstatement or omission, incorrect; therefore, the purchaser of the security relied on wrong information when buying or selling, and the issuer is consequently liable for value or opportunity lost.

Materiality is connected to the idea of reliance. For liability to arise, the plaintiff has to prove that they actually relied upon (as in, cared about) the wrong information when making a purchase. At its extremes, reliance is easy to understand. Some parts of the offering or disclosure documents (for example, financial statements) are obviously important. Other parts (the spelling of the surname of the chair of the Audit Committee) are clearly irrelevant, or immaterial, to whether a purchaser will want to buy the securities. Between these extremes, one finds the majority of the documents at issue and a vast grey area of potential reliance, depending both on the nature of the issuer and the nature of the buyer.

The Supreme Court of Canada wisely chose, in the 2011 decision in Sharbern Holding Inc. v. Vancouver Airport Centre Ltd.2 ("Sharbern") to inculcate a "reasonable investor" test in Canadian securities law. The Sharbern case is discussed here in detail. A statement is "material" if the information in question would matter (i.e., be relied upon) to the reasonable, hypothetical investor when considering the investment. Whether or not the investor actually relied on the information is not considered in the "reasonable investor" test.

This benefits everybody: the investor does not have to establish their particular reliance, which can be complex from an evidentiary standpoint; the issuer is not beset by bizarre investors who purport to care about minutia.

Class Proceedings

Class actions feature an early stage, known as "certification", in which the court blesses the class claim as legitimate and as an appropriate means of conduct. Fighting certification can be a worthwhile tactic for the issuer, particularly if the individual plaintiffs lack the means to act on their own accord.

In Ontario, the test for certification is set out in section 5(1) of the Class Proceedings Act.3 A significant part of that test is that "the claims or defences of the class members raise common issues". The "common issues" requirement is a feature of US law and is the plank on which an absence of materiality could lead to the class remaining uncertified. In short, from the plaintiff's perspective, there is no such thing as "collective reliance" – either each plaintiff relied on the false information, or they did not. A class composed of individuals who might and might not have relied on the information is not a class with common issues to try in court.

In Canada, one might think that Sharbern delivered a form of "collective reliance" to the benefit of plaintiffs in a class action. With the "reasonable investor" test, the plaintiffs need not worry about their own individual reliance situation. The law is confused, however, thanks to the more recent decision of the Ontario Superior Court of Justice in Green v. Canadian Imperial Bank of Commerce4 ("Green"). In Green, the court denied certification of a class action by CIBC shareholders based on the bank's exposure to the subprime crisis. The court in Green accepts that Sharbern "re-affirms the need to establish reliance in a common law misrepresentation claim", but misapplies the reasonable investor test by looking for individual reliance, which cannot be established on a class-wide basis.5

As an aside, the proposed representative plaintiffs in Green might give rise to second thoughts on the merits of the reasonable investor test. Mr. Green was an aficionado of share certificates. The disclosure of CIBC was hardly a factor when deciding whether to add a CIBC share certificate to his collection. The other representative plaintiff, a Mrs. Bell, invested through her husband, leaving the whole task to him. She was therefore totally unaware of what CIBC had disclosed.

The Amgen Decision

Amgen is a biotechnology company. The plaintiffs, a consortium of six state pension and nine state trust funds in Connecticut, alleged that Amgen misrepresented the safety of two anemia drugs it was producing. Clinical trials may have suggested that the drugs could harm cancer patients. The FDA expressed concern about the drugs' use, causing a 9% drop in Amgen's share price.

In the United States, s. 10(b) of the Securities Exchange Act of 19346 with SEC Rule 10b-57 creates a plaintiff-side obligation to establish reliance; i.e. each purchaser of securities must show they relied on the misrepresentation in question to have a claim against the issuer. As stated above, this is a difficult evidentiary challenge for a potential plaintiff.

The United States Supreme Court created an avenue to avoid that burden in the form of the "fraud on the market" theory of loss. The concept, as described by Justice Blackmun in Basic Inc. v. Levinson8 ("Levinson"), is that the price of a security is a function of the company and its business. Misleading statements therefore have the effect of defrauding purchasers of the delta between the "true" and "fraudulent" share value, regardless of reliance. The fraud on the market theory requires the securities to be traded in an efficient market and that the misrepresentation in question was made publicly. Reliance is not discharged by pleading the fraud on the market theory; rather, it is presumed and demonstrated objectively – a "reasonable investor" standard much like Sharbern.

Amgen is a "fraud on the market" ("FOTM") case. The United States Supreme Court, in a 6-3 decision written by Justice Ginsberg, found that, as materiality in fraud on the market situations is evaluated according to an objective standard, there can be no doubt that the degree of materiality of Amgen's misrepresentations on the anemia drugs is a common question to all class members. Either the reliance is objectively reasonable, or it isn't; the particular degrees of concern of each class member/investor are irrelevant. Amgen, thanks to the alignment of the fraud on the market theory and the reasonable investor test, clarifies the class certification requirement.

FOMO on FOTM?

The courts in Canada have rejected the fraud on the market theory. The most high profile case touching on this issue is Carom v. Bre-X Minerals Ltd.,9 in which the court in Ontario suggests the fraud on the market theory springs from the particular statutory context in which it originated, i.e. the restrictions in Rule 10b-5. This is, arguably, precisely not what the court was seeking to achieve in Levinson. The fraud on the market theory is as much a workaround as a statutory construct. Despite this misunderstanding, it doesn't exist here.

The absence of fraud on the market in Canada was noted by the court in Green,10 and might be suggested by some as the reason why Amgen is irrelevant in this jurisdiction. This viewpoint would not be accurate. The fraud on the market theory is the device by which the materiality standards in Canada and the United States happen to align. The aims of both courts, we speculate, in both Sharbern and Levinson were the same – to give comfort on what degree of misrepresentation opens the doors to a lawsuit.

Finally, we are not completely without the effect of the fraud on the market theory in Canada. The court in Green observes that s. 138.3 of the Ontario Securities Act,11 (and its equivalents in other provinces) which creates a right of action for misrepresentations operating on secondary market participants, was enacted in part to compensate for the absence of the fraud on the market theory in this country.

Squaring Sharbern and Green so the Result is Amgen

One possible way for the Green and Sharbern decisions to co-exist without confusion would be to have both an objective and subjective test of reliance. The test would have two stages: first, the court would ask if the misrepresentation at issue is one that would concern the reasonable investor (the objective test). If the court found the misrepresentation to be material to the reasonable investor, it would then ask if the actual investors/plaintiffs in fact relied on the misrepresentation. The two-stage test can be summarized by asking "was the plaintiffs' reliance reasonable?" On the court's reasoning in Green, there would still be no class action certification as long as any part of the materiality test is subjective.

There are two problems with this two-stage test: one, this was emphatically not what was prescribed in Sharbern, which was both a class action and a decision of the highest court in Canada; and two, this type of test does nothing to encourage accurate disclosure, as it further removes the plaintiffs from being able to sue when the disclosure is faulty.

Another way of squaring the Green and Sharbern decisions would be to ignore the substance of Green and accept the procedure. The result of this approach would be that materiality remains a burden on the plaintiffs at the certification stage of a class action, but the test would be an objective one. The natural evolution from this position is Amgen: if the materiality standard is the same for each investor, and is analyzed objectively, it is a common issue for all investors and would not foil the approval of a class.

The Significance of Amgen for Canadians

Although the Canadian courts need not, and should not, devote much thought to the class action certification procedure in the United States, it is of general concern that dramatic differences do not arise between the process there and here. The United States Supreme Court reached a common-sense decision in Amgen; we would benefit in Canada from evolving our position in that direction.

The United States Supreme Court's decision also heralds the prospect of yet more securities class actions succeeding in certification there (and consequently, more such actions being started, at least, here, if the securities were also issued into Canada). Although materiality will still need to be proven at the trial of a claim, dropping the examination of the question at the certification stage removes a barrier for plaintiffs seeking to press forward to a settlement. The truth of all class action litigation is that settlement for business or economic reasons, regardless of the merits of the case, is a likely outcome. Class actions are expensive and often damaging to public and investor relations. Fighting certification, from the issuer's standpoint, can be tantamount to fighting the whole case.

If you have any questions concerning this bulletin, please contact the authors or any member of the Davis Litigation Group.

Footnotes

1 No. 11-1085,—S. Ct (US)

2 [2011] 2 S.C.R. 175

3 S.O. 1992, c. 6

4 2012 ONSC 3637

5 Green, at para. 600

6 15 U.S.C. § 78a et seq.

7 17 C.F.R. 240 10b-5

8 485 U.S. 224 (1988)

9 (1998) 41 O.R. (3d) 780

10 Green, at para. 595

11 R.S.O. 1990, c. S.5

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions